Drug Safety

, Volume 31, Issue 8, pp 643–665 | Cite as

A Benefit-Risk Assessment of Benzbromarone in the Treatment of Gout

Was its Withdrawal from the Market in the Best Interest of Patients?
  • Ming-Han H. Lee
  • Garry G. Graham
  • Kenneth M. Williams
  • Richard O. Day
Review Article


Benzbromarone, a potent uricosuric drug, was introduced in the 1970s and was viewed as having few associated serious adverse reactions. It was registered in about 20 countries throughout Asia, South America and Europe. In 2003, the drug was withdrawn by Sanofi-Synthélabo, after reports of serious hepatotoxicity, although it is still marketed in several countries by other drug companies. The withdrawal has greatly limited its availability around the world, and increased difficulty in accessing it in other countries where it has never been available.

The overall aim of this paper is to determine if the withdrawal of benzbromarone was in the best interests of gouty patients and to present a benefit-risk assessment of benzbromarone. To determine this, we examined (i) the clinical benefits associated with benzbromarone treatment and compared them with the success of alternative therapies such as allopurinol and probenecid, particularly in patients with renal impairment; (ii) the attribution of the reported cases of hepatotoxicity to treatment with benzbromarone; (iii) the incidence of hepatotoxicity possibly due to benzbromarone; (iv) adverse reactions to allopurinol and probenecid. From these analyses, we present recommendations on the use of benzbromarone.

Large reductions in plasma urate concentrations in patients with hyperuricaemia are achieved with benzbromarone and most patients normalize their plasma urate. The half-life of benzbromarone is generally short (about 3 hours); however, a uricosuric metabolite, 6-hydroxybenzbromarone, has a much longer half-life (up to 30 hours) and is the major species responsible for the uricosuric activity of benzbromarone, although its metabolism by cytochrome P450 (CYP) 2C9 in the liver may vary between patients as a result of polymorphisms in this enzyme. It is effective in patients with moderate renal impairment. Standard dosages of benzbromarone (100 mg/day) tend to produce greater hypouricaemic effects than standard doses of allopourinol (300 mg/day) or probenecid (1000 mg/ day).

Adverse effects associated with benzbromarone are relatively infrequent, but potentially severe. Four cases of benzbromarone-induced hepatotoxicity were identified from the literature. Eleven cases have been reported by Sanofi-Synthélabo, but details are not available in the public domain. Only one of the four published cases demonstrated a clear relationship between the drug and liver injury as demonstrated by rechallenge. The other three cases lacked incontrovertible evidence to support a diagnosis of benzbromarone-induced hepatotoxicity. If all the reported cases are assumed to be due to benzbromarone, the estimated risk of hepatotoxicity in Europe was approximately 1 in 17 000 patients but may be higher in Japan.

Benzbromarone is also an inhibitor of CYP2C9 and so may be involved in drug interactions with drugs dependent on this enzyme for clearance, such as warfarin. Alternative drugs to benzbromarone have significant adverse reactions. Allopurinol is associated with rare life-threatening hypersensitivity syndromes; the risk of these reactions is approximately 1 in 56 000. Rash occurs in approximately 2% of patients taking allopurinol and usually leads to cessation of prescription of the drug. Probenecid has also been associated with life-threatening reactions in a very small number of case reports, but it frequently interacts with many renally excreted drugs. Febuxostat is a new xanthine oxidoreductase inhibitor, which is still in clinical trials, but abnormal liver function is the most commonly reported adverse reaction.

Even assuming a causal relationship between benzbromarone and hepatotoxicity in the identified cases, benefit-risk assessment based on total exposure to the drug does not support the decision by the drug company to withdraw benzbromarone from the market given the paucity of alternative options. It is likely that the risks of hepatotoxicity could be ameliorated by employing a graded dosage increase, together with regular monitoring of liver function. Determination of CYP2C9 status and consideration of potential interactions through inhibition of this enzyme should be considered. The case for wider and easier availability of benzbromarone for treating selected cases of gout is compelling, particularly for patients in whom allopurinol produces insufficient response or toxicity.

We conclude that the withdrawal of benzbromarone was not in the best interest of patients with gout.


  1. 1.
    Sternon J, Kocheleff P, Couturier E, et al. Hypouricemizing effect of benzbromarone: study of 24 cases (preliminary results) [in French]. Acta Clin Belg 1967; 22(5): 285–93PubMedGoogle Scholar
  2. 2.
    Nivet M, Marcovici J, Compagnon P, et al. The hypo-uricemic action of oral benziodarone [in French]. Sem Hop 1967 Jan 8; 43(2): 135–8PubMedGoogle Scholar
  3. 3.
    Bekaert J, Deltour G, Broekhuysen J. Research on the benzofuran series III: study of the thyroid function in man during the administration of an iodized bensofuran derivative (Benziodarone) [in German]. Arch Int Pharmacodyn Ther 1961 Jul 1; 132: 339–48PubMedGoogle Scholar
  4. 4.
    Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 May 23; 417(6887): 447–52PubMedGoogle Scholar
  5. 5.
    Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof. European patent EP1767531 [online]. Available from URL: http://www.freepatentsonline.com/EP1767531.html[Accessed 2008 May 19]
  6. 6.
    Maurer H, Wollenberg P. Urinary metabolites of benzbromarone in man. Arzneimittelforschung 1990 Apr; 40(4): 460–2PubMedGoogle Scholar
  7. 7.
    de Vries JX, Walter-Sack I, Ittensohn A, et al. Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite. Clin Investig 1993 Nov; 71(11): 947–52PubMedCrossRefGoogle Scholar
  8. 8.
    McDonald MG, Rettie AE. Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 2007 Dec; 20(12): 1833–42PubMedCrossRefGoogle Scholar
  9. 9.
    van der Klauw MM, Houtman PM, Stricker BH, et al. Hepatic injury caused by benzbromarone. J Hepatol 1994 Mar; 20(3): 376–9PubMedCrossRefGoogle Scholar
  10. 10.
    Wagayama H, Shiraki K, Sugimoto K, et al. Fatal fulminant hepatic failure associated with benzbromarone [letter]. J Hepatol 2000 May; 32(5): 874PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki T, Suzuki T, Kimura M, et al. A case of fulminant hepatitis, possibly caused by benzbromarone [in Japanese]. Nippon Shokakibyo Gakkai Zasshi 2001 Apr; 98(4): 421–5PubMedGoogle Scholar
  12. 12.
    Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002 May; 17(5): 625–6PubMedCrossRefGoogle Scholar
  13. 13.
    Jansen TL, Reinders MK, van Roon EN, et al. Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? [letter]. Clin Exp Rheumatol 2004 Sep–Oct; 22(5): 651PubMedGoogle Scholar
  14. 14.
    Thomson Healthcare. Benzbromarone. In: Martindale: the complete drug reference (internet database) [online]. Available from URL: http://www.medicinescomplete.com/mc/ [Accessed 2008 May 5]
  15. 15.
    Nakamura N. Efficacy of benzbromarone for hyperuricemia [in Japanese]. Rinsho to Kenkyu 1971; 48(11): 2956–60Google Scholar
  16. 16.
    de Gery A, Auscher C, Saporta L, et al. Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran. Adv Exp Med Biol 1974; 41: 683–9PubMedGoogle Scholar
  17. 17.
    Ravera R. Benzbromarone in the treatment of hyperuricemias [in Italian]. Minerva Med 1975 Mar 7; 66(17): 783–800PubMedGoogle Scholar
  18. 18.
    Didier M, Olmer M. Hypouricemic effect of benzbromarone especially in kidney failure [in French]. Sem Hop 1978 Apr; 54(9–12): 463–5PubMedGoogle Scholar
  19. 19.
    Ferber H, Bader U, Matzkies F. The action of benzbromarone in relation to age, sex and accompanying diseases. Adv Exp Med Biol 1980; 122A: 287–94PubMedGoogle Scholar
  20. 20.
    Bluestone R, Klinenberg J, Lee IK. Benzbromarone as a long-term uricosuric agent. Adv Exp Med Biol 1980; 122A: 283–6PubMedGoogle Scholar
  21. 21.
    Scott JT. Comparison of allopurinol and probenecid. Ann Rheum Dis 1966 Nov; 25(6): 623–6PubMedGoogle Scholar
  22. 22.
    Zurcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9(5): 548–51PubMedGoogle Scholar
  23. 23.
    Nakamura N. Efficacy of benzbromarone for hyperuricemia: part 2. Comparison with allopurinol [in Japanese]. Rinsho to Kenkyu 1972; 49(5): 1381–4Google Scholar
  24. 24.
    Mertz DP. The uric acid-lowering action of benzbromarone effervescent granules and allopurinol: comparative studies (author’s translation) [in German]. MMW Munch Med Wochenschr 1978 Oct 20; 120(42): 1387–90PubMedGoogle Scholar
  25. 25.
    Schepers GW. Benzbromarone therapy in hyperuricaemia: comparison with allopurinol and probenecid. J Int Med Res 1981; 9(6): 511–5PubMedGoogle Scholar
  26. 26.
    Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998 Sep; 57(9): 545–9PubMedCrossRefGoogle Scholar
  27. 27.
    Perez-Ruiz F, Calabozo M, Fernandez-Lopez M, et al. Treatment of chronic gout in patients with renal function impairment. J Clin Rheumatol 1999; 5(2): 49–55PubMedCrossRefGoogle Scholar
  28. 28.
    Hanvivadhanakul P, Akkasilpa S, Deesomchok U. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients. J Med Assoc Thai 2002 Jun; 85 Suppl. 1: S40–7PubMedGoogle Scholar
  29. 29.
    Liang L, Xu N, Zhang H, et al. A randomized controlled study of benzbromarone and probenecid in the treatment of gout. West China Medical Journal 1994; 9(4): 405–8Google Scholar
  30. 30.
    Mertz DP. Reducing the risks in the treatment of gout and hyperuricaemia (author’s translation) [in German]. Dtsch Med Wochenschr 1976 Aug 27; 101(35): 1288–92PubMedCrossRefGoogle Scholar
  31. 31.
    Frerick H, Schaefer J, Rabinovici K, et al. Longterm treatment of hyperurikemia and gout; randomised study. Therapiewoche 1987; 37(36): 3379–84Google Scholar
  32. 32.
    Berg H. Effectiveness and tolerance of long-term uricosuric treatment [in German]. Z Gesamte Inn Med 1990 Dec 1; 45(23): 719–20PubMedGoogle Scholar
  33. 33.
    Akkasilpa S, Osiri M, Deesomchok U, et al. The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia. J Med Assoc Thai 2004 Sep; 87(9): 1087–91PubMedGoogle Scholar
  34. 34.
    Arntz HR, Dreykluft HR, Leonhardt H. Effect of uric acid lowering drugs in low dosage in patients with hyperuricemia and hypertriglyceridemia in a randomized group study [in German]. Fortschritte der Medizin 1979; 97(27): 1212–4PubMedGoogle Scholar
  35. 35.
    Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Vital Health Stat 10 1999 Oct; (200): 1–203Google Scholar
  36. 36.
    Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007 Aug; 3(8): 443–9PubMedCrossRefGoogle Scholar
  37. 37.
    Stewart OJ, Silman AJ. Review of UK data on the rheumatic diseases: 4.Gout. Br J Rheumatol1990 Dec; 29(6): 485–8PubMedCrossRefGoogle Scholar
  38. 38.
    Arromdee E, Michet CJ, Crowson CS, et al. Epidemiology of gout: is the incidence rising? J Rheumatol 2002 Nov; 29(11): 2403–6PubMedGoogle Scholar
  39. 39.
    Kim KY, Ralph Schumacher H, Hunsche E, et al. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003 Jun; 25(6): 1593–617PubMedCrossRefGoogle Scholar
  40. 40.
    Emmerson BT. The management of gout. N Engl J Med 1996 Feb 15; 334(7): 445–51PubMedCrossRefGoogle Scholar
  41. 41.
    Gonzalez AA, Puig JG, Mateos FA, et al. Should dietary restrictions always be prescribed in the treatment of gout? Adv Exp Med Biol 1989; 253A: 243–6PubMedCrossRefGoogle Scholar
  42. 42.
    Ralston SH, Capell HA, Sturrock RD. Alcohol and response to treatment of gout. BMJ (Clin Res Ed) 1988 Jun 11; 296(6637): 1641–2CrossRefGoogle Scholar
  43. 43.
    Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout: a systematic review. Rheumatology (Oxford) 2006 Nov; 45(11): 1422–31CrossRefGoogle Scholar
  44. 44.
    Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005 May; 17(3): 319–24PubMedCrossRefGoogle Scholar
  45. 45.
    Bland JM, Altman DG. Statistics notes: the odds ratio. BMJ 2000 May 27; 320(7247): 1468PubMedCrossRefGoogle Scholar
  46. 46.
    Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993 Mar; 27(3): 337–43PubMedGoogle Scholar
  47. 47.
    Ferraz MB, O’Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995 May; 22(5): 908–14PubMedGoogle Scholar
  48. 48.
    Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006 Oct; 65(10): 1312–24PubMedCrossRefGoogle Scholar
  49. 49.
    Day RO, Miners JO, Birkett DJ, et al. Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 1988 Oct; 26(4): 423–8PubMedCrossRefGoogle Scholar
  50. 50.
    Emmerson BT, Gordon RB, Cross M, et al. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987 Dec; 26(6): 445–9PubMedCrossRefGoogle Scholar
  51. 51.
    Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007 Aug; 46(8): 1372–4CrossRefGoogle Scholar
  52. 52.
    Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006 Aug; 33(8): 1646–50PubMedGoogle Scholar
  53. 53.
    Walter-Sack I, de Vries JX, Ernst B, et al. Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients: therapeutic equivalence to allopurinol. J Rheumatol 1996 Mar; 23(3): 498–501PubMedGoogle Scholar
  54. 54.
    Elion GB, Yu TF, Gutman AB, et al. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968 Jul; 45(1): 69–77PubMedCrossRefGoogle Scholar
  55. 55.
    Gibson T, Rodgers V, Potter C, et al. Allopurinol treatment and its effect on renal function in gout: a controlled study. Ann Rheum Dis 1982 Feb; 41(1): 59–65PubMedCrossRefGoogle Scholar
  56. 56.
    Tarng DC, Lin HY, Shyong ML, et al. Renal function in gout patients. Am J Nephrol 1995; 15(1): 31–7PubMedCrossRefGoogle Scholar
  57. 57.
    Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984 Jan; 76(1): 47–56PubMedCrossRefGoogle Scholar
  58. 58.
    Walter-Sack I, de Vries JX, Ittensohn A, et al. Benzbromarone disposition and uricosuric action; evidence for hydroxilation instead of debromination to benzarone. Klin Wochenschr 1988 Feb 15; 66(4): 160–6PubMedCrossRefGoogle Scholar
  59. 59.
    Jain AK, Ryan JR, McMahon FG, et al. Effect of single oral doses of benzbromarone on serum and urinary uric acid. Arthritis Rheum 1974 Mar–Apr; 17(2): 149–57PubMedCrossRefGoogle Scholar
  60. 60.
    Broekhuysen J, Pacco M, Sion R, et al. Metabolism of benzbromarone in man. Eur J Clin Pharmacol 1972 Mar; 4(2): 125–30PubMedCrossRefGoogle Scholar
  61. 61.
    Kunishima C, Inoue I, Oikawa T, et al. The metabolism, toxicity and pharmacological studies of benzbromarone (Urinorm). J Saitama Med School 2003; 30(4): 187–94Google Scholar
  62. 62.
    Uchida S, Shimada K, Misaka S. Influences of CYP2C9 genotype on pharmacokinetics and pharmacodynamics of benzbromarone [abstract P 13. Clin Pharmacol Ther 2006; 79(2): 13CrossRefGoogle Scholar
  63. 63.
    Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 2002 Apr; 12(3): 251–63PubMedCrossRefGoogle Scholar
  64. 64.
    Walter-Sack I, de Vries JX, von Bubnoff A, et al. Biotransformation and uric acid lowering effect of benzbromarone in patients with liver cirrhosis: evidence for active benzbromarone metabolites? Eur J Med Res 1995 Oct 16; 1(1): 16–20PubMedGoogle Scholar
  65. 65.
    Heel RC, Brogden RN, Speight TM, et al. Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia. Drugs 1977; 14: 349–66PubMedCrossRefGoogle Scholar
  66. 66.
    Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007 Mar; 24(3): 450–70PubMedCrossRefGoogle Scholar
  67. 67.
    Ichida K, Hosoyamada M, Kimura H, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 2003 Jan; 63(1): 143–55PubMedCrossRefGoogle Scholar
  68. 68.
    Sommers DK, Van Wyk M, Moncrieff J, et al. Renal Secretory mechanisms for ampicillin and uric acid. S Afr Med J 1987; 83: 114–5Google Scholar
  69. 69.
    Politta G, Berthoud S, Gaudin G, et al. Mechanism of uricosuric action of benzbromaron [in French]. Schweiz Rundsch Med Prax 1973 Oct 30; 62(44): 1345–50PubMedGoogle Scholar
  70. 70.
    Kippen I, Nakata N, Honda S, et al. Uptake of uric acid by separated renal tubules of the rabbit. II. Effects of drugs. J Pharmacol Exp Ther 1977 Apr; 201(1): 226–32PubMedGoogle Scholar
  71. 71.
    Moriwaki Y, Yamamoto T, Takahashi S, et al. Analysis of uric acid transport in renal tubules using benzbromarone and pyrazinamide. Int J Clin Pharmacol Ther Toxicol 1990 Feb; 28(2): 84–8PubMedGoogle Scholar
  72. 72.
    Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. NZ Med J 2005 Jun 24; 118(1217): U1528Google Scholar
  73. 73.
    Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of uratelowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002 Aug; 47(4): 356–60PubMedCrossRefGoogle Scholar
  74. 74.
    Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981 May 9; 59(20): 701–6PubMedGoogle Scholar
  75. 75.
    Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300(26): 1459–68PubMedCrossRefGoogle Scholar
  76. 76.
    Mertz DP, Eichhorn R. Does benzbromarone in therapeutic doses raise renal excretion of oxipurinol? Klin Wochenschr 1984 Dec 17; 62(24): 1170–2PubMedCrossRefGoogle Scholar
  77. 77.
    Ruffer C, Zorn G, Henkel E, et al. Influence of benzbromarone on the pharmacokinetics and pharmacodynamics of oxipurinol [in German]. Arzneimittelforschung 1982; 32(9): 1149–52PubMedGoogle Scholar
  78. 78.
    Loffler W, Grobner W, Zollner N. Uric acid-lowering effect of a combination of benzbromarone and allopurinol: studies under standardized dietary conditions [in German]. Arzneimittelforschung 1983; 33(12): 1687–91PubMedGoogle Scholar
  79. 79.
    Yamamoto T, Moriwaki Y, Takahashi S, et al. Effects of pyrazinamide, probenecid, and benzbromarone on renal excretion of oxypurinol. Ann Rheum Dis 1991 Sep; 50(9): 631–3PubMedCrossRefGoogle Scholar
  80. 80.
    Bartels EC, Matossian GS. Gout: six-year follow-up on probenecid (benemid) therapy. Arthritis Rheum 1959 Jun; 2(3): 193–202PubMedCrossRefGoogle Scholar
  81. 81.
    Thompson GR, Duff IF, Robinson WD, et al. Long term uricosuric therapy in gout. Arthritis Rheum 1962 Aug; 5: 384–96PubMedCrossRefGoogle Scholar
  82. 82.
    Yue TF, Gutman AB. Effect of allopurinol (4-hydroxypyrazolo-(3,4-D)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am J Med 1964 Dec; 37: 885–98PubMedCrossRefGoogle Scholar
  83. 83.
    Reinders MK, van Roon EN, Houtman PM, et al. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol 2007; 26(9): 1459–65PubMedCrossRefGoogle Scholar
  84. 84.
    Stocker SL, Williams KM, McLachlan AJ, et al. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008; 47(2): 111–8PubMedCrossRefGoogle Scholar
  85. 85.
    Wallis RB. Mechanisms of action of sulphinpyrazone. Thromb Res Suppl 1983; 4: 31–8PubMedCrossRefGoogle Scholar
  86. 86.
    Pedersen AK, FitzGerald GA. The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. Circulation 1985 Dec; 72(6): 1164–76PubMedCrossRefGoogle Scholar
  87. 87.
    Kersley GD. Allopurinol in primary gout with and after the administration of uricosuric agents. Ann Rheum Dis 1966 Nov; 25 (6 Suppl.): 643–4PubMedGoogle Scholar
  88. 88.
    Tomlinson B. Febuxostat (Teijin/Ipsen/TAP). Curr Opin Investig Drugs 2005 Nov; 6(11): 1168–78PubMedGoogle Scholar
  89. 89.
    Schumacher HR, Becker Jr MA, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005 Dec 8; 353(23): 2450–61PubMedCrossRefGoogle Scholar
  90. 90.
    Kaufmann P, Torok M, Hanni A, et al. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005 Apr; 41(4): 925–35PubMedCrossRefGoogle Scholar
  91. 91.
    Bichet N, Cahard D, Fabre G, et al. Toxicological studies on a benzofuran derivative: III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol Appl Pharmacol 1990 Dec; 106(3): 509–17PubMedCrossRefGoogle Scholar
  92. 92.
    Butler EG, Ichida T, Maruyama H, et al. Toxicological studies on a benzofurane derivative. II. Demonstration of peroxisome proliferation in rat liver. Toxicol Appl Pharmacol 1990 Dec; 106(3): 500–8PubMedCrossRefGoogle Scholar
  93. 93.
    Parzefall W, Schuppler J, Barthel G, et al. Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver. Toxicol Appl Pharmacol 1990 Dec; 106(3): 482–99PubMedCrossRefGoogle Scholar
  94. 94.
    Enayetallah AE, French RA, Thibodeau MS, et al. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52(4): 447–54PubMedCrossRefGoogle Scholar
  95. 95.
    Takahashi H, Sato T, Shimoyama Y, et al. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 1999 Dec; 66(6): 569–81PubMedCrossRefGoogle Scholar
  96. 96.
    Sevilla-Mantilla C, Ortega L, Agundez JA, et al. Leflunomide-induced acute hepatitis. Dig Liver Dis 2004 Jan; 36(1): 82–4PubMedCrossRefGoogle Scholar
  97. 97.
    Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 Suppl. 2: 12–21CrossRefGoogle Scholar
  98. 98.
    Lilly MB, Omura GA. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid. Cancer Chemother Pharmacol 1985; 15(3): 220–2PubMedCrossRefGoogle Scholar
  99. 99.
    Chaibriant H. Stop marketing of proprietary medical product DESURIC(Rm) (benzbromarone) [online]. Available from URL: http://afssaps.sante.fr/htm/10/filcoprs/030403.htm [Accessed 2008 May 19]
  100. 100.
    Benzbromarone: withdrawn due to reports of liver damage. WHO Pharmaceuticals Newsletter; 2003: 1Google Scholar
  101. 101.
    Department des alertes [online]. Available from: http://afssap-s.sante.fr/pdf/5/bilan04b.pdf [Accessed 2008 May 19]
  102. 102.
    Masbernard A, Giudicelli CP. Ten years’ experience with benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9(5): 548–51Google Scholar
  103. 103.
    Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006 Feb 16; 354(7): 731–9PubMedCrossRefGoogle Scholar
  104. 104.
    Department of Economic and Social Affairs United Nations. Population and vital statistics report series A Vol. LIX, No. 1. New York: United Nations; 2007Google Scholar
  105. 105.
    Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clinic Proceedings 2006; 81: 925–34PubMedCrossRefGoogle Scholar
  106. 106.
    Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36(2): 451–5PubMedCrossRefGoogle Scholar
  107. 107.
    McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981 Jun; 40(3): 245–9PubMedCrossRefGoogle Scholar
  108. 108.
    Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004 Nov; 71(6): 481–5PubMedCrossRefGoogle Scholar
  109. 109.
    Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg 1996 Dec; 15(4): 250–7PubMedCrossRefGoogle Scholar
  110. 110.
    Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population-based study with particular reference to reactions caused by drags among outpatients. Arch Dermatol 1990 Jan; 126(1): 43–7PubMedCrossRefGoogle Scholar
  111. 111.
    Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995 Dec 14; 333(24): 1600–7PubMedCrossRefGoogle Scholar
  112. 112.
    Chung Y. Utilisation of allopurinol in the Australian community. Intern Med J. In PressGoogle Scholar
  113. 113.
    Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005 Mar 15; 102(11): 4134–9PubMedCrossRefGoogle Scholar
  114. 114.
    Myers KW, Katial RK, Engler RJ. Probenecid hypersensitivity in AIDS: a case report. Ann Allergy Asthma Immunol 1998 May; 80(5): 416–8PubMedCrossRefGoogle Scholar
  115. 115.
    Izzedine H, Brocheriou I, Becart J, et al. Probenecid-induced membranous nephropathy. Nephrol Dial Transplant 2007 Aug; 22(8): 2405–6PubMedCrossRefGoogle Scholar
  116. 116.
    Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981 Mar–Apr; 6(2): 135–51PubMedCrossRefGoogle Scholar
  117. 117.
    Szczeklik A, Czerniawska-Mysik G, Nizankowska E. Sulfinpyrazone and aspirin-induced asthma. N Engl J Med 1980 Sep 18; 303(12): 702–3PubMedGoogle Scholar
  118. 118.
    Committee on the Review of Medicines. Recommendations on phenylbutazone, oxyphenbutazone, feprazone, allopurinol, colchicine, probenecid, and sulphinpyrazone. BMJ 1978 Jun 3; 1(6125): 1466–7CrossRefGoogle Scholar
  119. 119.
    Pedersen AK, Jakobsen P, Kampmann JP, et al. Clinical pharmacokinetics and potentially important drug interactions of sulphinpyrazone. Clin Pharmacokinet 1982 Jan–Feb; 7(1): 42–56PubMedCrossRefGoogle Scholar
  120. 120.
    Caforio AL, Gambino A, Tona F, et al. Sulfinpyrazone reduces cyclosporine levels: a new drag interaction in heart transplant recipients. J Heart Lung Transplant 2000 Dec; 19(12): 1205–8PubMedCrossRefGoogle Scholar
  121. 121.
    Ferrara LA, Mancini M, Marotta T, et al. Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. Eur J Clin Pharmacol 1986; 29(6): 717–9PubMedCrossRefGoogle Scholar
  122. 122.
    Neogi T, Hunter DJ, Chaisson CE, et al. Frequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal study. J Rheumatol 2006 Jan; 33(1): 104–9PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  • Ming-Han H. Lee
    • 1
  • Garry G. Graham
    • 1
  • Kenneth M. Williams
    • 1
  • Richard O. Day
    • 1
  1. 1.Department of Clinical Pharmacology & ToxicologySt Vincent’s Hospital, University of New South WalesSydneyAustralia
  2. 2.Department of Clinical Pharmacology & ToxicologySt Vincent’s HospitalDarlinghurstAustralia

Personalised recommendations